Ampion demonstrates safety in COVID patients and initiates global trial for intravenous Ampion

Ampion demonstrates safety in COVID patients and initiates global trial for intravenous Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it hascompleted its Phase I clinical trial and has initiated the first steps for a global Phase II clinical trial for... Read More

Friday December 18, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, COVID-19, Ampion

Ampio enters into collaborative research agreements to explore additional clinical indications for Ampion

Ampio enters into collaborative research agreements to explore additional clinical indications for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug,... Read More

Monday December 14, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, FDA, COVID-19

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment following... Read More

Friday December 4, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, COVID-19, Inhaled Ampion

Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress

Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the second group in the Phase I inhaled Ampionclinical study is being treated following clearance by the Safety Monitoring... Read More

Wednesday November 11, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Inhaled Ampion, Michael Macaluso, COVID-19

Ampio begins Phase 1 clinical trial of inhaled Ampion for COVID-19

Ampio begins Phase 1 clinical trial of inhaled Ampion for COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it hasbegun recruiting and enrolling patients in a Phase Imulti-center, randomized, controlled trial for a total of 40... Read More

Thursday October 29, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, Michael Macaluso

FDA grants IND and approves clinical trial protocol of inhaled Ampion for COVID-19 patients

FDA grants IND and approves clinical trial protocol of inhaled Ampion for COVID-19 patients

ENGLEWOOD-- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it has received an Investigational New Drug designation from the U.S. Food and Drug Administration, allowing the company to... Read More

Monday September 21, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, FDA

Ampio announces enrollment completion for IV COVID-19 clinical trial, update on OAK clinical trial

Ampio announces enrollment completion for IV COVID-19 clinical trial, update on OAK clinical trial

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced enrollment has been completed for the AmpionPhase I US-based clinical trial for IV treatment of COVID-19 patients requiring... Read More

Tuesday September 8, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, COVID-19

Ampio starts patient enrollment in its Ampion COVID-19 program

Ampio starts patient enrollment in its Ampion COVID-19 program

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced it is actively working on development of therapies for patients infected with COVID-19. Ampio said patients are... Read More

Thursday July 23, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19